Piramal Pharma announced its strategic partnership with Korean biotech firm IntoCell to expand its offerings in the rapidly growing antibody-drug conjugate (ADC) and bioconjugate market. The formalized agreement centers on integrating IntoCell’s proprietary payload-linker technologies - including OHPAS linker and novel payload systems such as Duocarmycin, Nexatecan, and iso-Nexatecan - with Piramal’s established development and manufacturing platform.
This collaboration allows Piramal to broaden its service portfolio, providing clients a wider range of ADC payload-linkers, accelerated timelines, and enhanced bioconjugation capabilities. Central to the partnership is the support for ADCelerate™, Piramal’s branded program for rapid and integrated ADC development, which streamlines the transition from concept to clinical supply and aims to compress timelines for investigational drug submissions to as few as twelve months. By leveraging IntoCell’s drug-linker technologies, Piramal expects to deliver advanced conjugation solutions and further efficiency for customers seeking innovative targeted therapeutics.
The CEOs of both companies expressed enthusiasm, emphasizing the combined expertise and commitment to mutual success and better patient outcomes. Peter DeYoung, CEO of Piramal Global Pharma, underscored the partnership’s role in redefining industry standards and enabling clients to innovate in highly specialized segments. Tae Kyo Park, CEO of IntoCell, also voiced optimism for long-term collaboration and value creation in the global bioconjugate market.